Fresh analysis suggests that individuals who stop using blockbuster slimming jabs like semaglutide or tirzepatide tend to recover reduced body mass much more quickly than those who end conventional lifestyle programs.
Research printed in a leading health publication demonstrates that while overweight individuals frequently drop substantial amounts of their body weight while using the jabs, the weight comes back at an average rate of nearly a kilo each month once they quit.
"Individuals purchasing these treatments must be informed of the risk of rapid rebound weight gain when the treatment is stopped," warns lead investigator Dr. Susan Jebb.
That rate of regain suggests a return to starting weight in about a year and a half.
Comparing Treatments
The analysis, which looked at dozens of studies involving thousands of patients, compared the results of these new drugs with older methods.
Scientists note that individuals who lose weight through dieting typically experience a less rapid creep back—perhaps 0.1 kg a month—once they finish.
The Reason for the Fast Regain
Nutrition scientists propose the mechanism of the injections is key to understanding the heightened weight return.
GLP-1 drugs imitate a body's own chemical called GLP-1, which moderates hunger.
"Artificially providing GLP-1 concentrations far above than the body's typical production might result in the body to produce less of its own natural hormone, and could diminish responsiveness to its actions," said Dr. Adam Collins, a dietetics specialist.
"Withdrawal of this hormone supplement means appetite is unsuppressed, making binge eating a significant risk."
A Lifelong Condition?
Health authorities suggest the jabs for people with obesity-related medical conditions, accompanied by recommended lifestyle changes.
Many experts say that, due to the high risk of weight regain, the therapy might need to be ongoing.
This perspective is reinforced by drug manufacturers, who say that the results "emphasize the chronic nature of excess weight," akin to managing conditions like hypertension.
Patient Experiences
People who have discontinued the jabs describe a sudden resurgence of hunger.
"It was like a trigger that goes on and you're instantly starving," said a patient.
This challenge is exacerbated if patients have not adopted permanent lifestyle or habit modifications during treatment.
Widespread Interest
Recent estimates suggest that millions of people in the UK have tried weight-loss jabs in the last 12 months, with demand being substantial.
- Use is higher among females compared to males.
- The 40s and 50s age group shows the highest level of interest.
- Many access the drugs through private prescriptions rather than the NHS.
Finally, clinicians stress that while GLP-1 drugs are effective agents for weight loss, they are not a permanent solution and lasting health benefits relies on integrated lifestyle support.
